JP7195934B2 - 硫黄含有化合物を含む微小粒子 - Google Patents

硫黄含有化合物を含む微小粒子 Download PDF

Info

Publication number
JP7195934B2
JP7195934B2 JP2018563831A JP2018563831A JP7195934B2 JP 7195934 B2 JP7195934 B2 JP 7195934B2 JP 2018563831 A JP2018563831 A JP 2018563831A JP 2018563831 A JP2018563831 A JP 2018563831A JP 7195934 B2 JP7195934 B2 JP 7195934B2
Authority
JP
Japan
Prior art keywords
composition
cysteamine
microparticles
composition according
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018563831A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517541A (ja
JP2019517541A5 (enExample
Inventor
オネイル デボラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NovaBiotics Ltd
Original Assignee
NovaBiotics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NovaBiotics Ltd filed Critical NovaBiotics Ltd
Publication of JP2019517541A publication Critical patent/JP2019517541A/ja
Publication of JP2019517541A5 publication Critical patent/JP2019517541A5/ja
Application granted granted Critical
Publication of JP7195934B2 publication Critical patent/JP7195934B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Pigments, Carbon Blacks, Or Wood Stains (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Accessories For Mixers (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2018563831A 2016-06-07 2017-06-06 硫黄含有化合物を含む微小粒子 Active JP7195934B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662346969P 2016-06-07 2016-06-07
US62/346,969 2016-06-07
GB1609940.0 2016-06-07
GBGB1609940.0A GB201609940D0 (en) 2016-06-07 2016-06-07 Microparticles
PCT/GB2017/051637 WO2017212249A1 (en) 2016-06-07 2017-06-06 Microparticles comprising a sulphur-containing compound

Publications (3)

Publication Number Publication Date
JP2019517541A JP2019517541A (ja) 2019-06-24
JP2019517541A5 JP2019517541A5 (enExample) 2020-07-09
JP7195934B2 true JP7195934B2 (ja) 2022-12-26

Family

ID=56508202

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018563831A Active JP7195934B2 (ja) 2016-06-07 2017-06-06 硫黄含有化合物を含む微小粒子

Country Status (16)

Country Link
US (1) US11369568B2 (enExample)
EP (1) EP3463325B1 (enExample)
JP (1) JP7195934B2 (enExample)
KR (1) KR102412212B1 (enExample)
CN (1) CN109310654A (enExample)
AU (1) AU2017277897B2 (enExample)
BR (1) BR112018075221B1 (enExample)
CA (2) CA3026743C (enExample)
DK (1) DK3463325T3 (enExample)
ES (1) ES2965017T3 (enExample)
FI (1) FI3463325T3 (enExample)
GB (1) GB201609940D0 (enExample)
MX (1) MX2018014278A (enExample)
SG (1) SG11201810934TA (enExample)
WO (1) WO2017212249A1 (enExample)
ZA (1) ZA201807852B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10905660B2 (en) 2016-06-07 2021-02-02 Novabiotics Limited Microparticles
EP3572068A1 (en) * 2018-05-22 2019-11-27 RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. New salt of cysteamine for the preparation of highly respirable particles
ES3024695T3 (en) * 2018-10-17 2025-06-05 Novabiotics Ltd Cysteamine for use in the treatment of lung diseases
JP2023540985A (ja) * 2020-09-03 2023-09-27 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 噴霧乾燥低吸湿性活性粉末組成物
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
CN118871100A (zh) * 2021-12-07 2024-10-29 西拉治疗公司 抗病毒治疗剂及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526735A (ja) 2004-12-30 2008-07-24 ドゥビエル カンパニー リミテッド 噴霧乾燥高分子型コレクチン属タンパク質及びその製造方法
US20120129946A1 (en) 2009-05-23 2012-05-24 Jess Gilbert Thoene Materials and methods for treating viral infections
JP2013082660A (ja) 2011-10-11 2013-05-09 Nico Puff Corp ニコチン薬の製造法およびその方法により製造される医薬
JP2014515356A (ja) 2011-05-19 2014-06-30 サヴァラ，インク． 乾燥粉末バンコマイシン組成物および関連する方法
WO2015054574A1 (en) 2013-10-11 2015-04-16 Zisman Lawrence S Spray dry formulations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8901570D0 (sv) 1989-05-02 1989-05-02 Draco Ab Organic salts of cysteine derivatives
AR057623A1 (es) 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
AU2007338210B2 (en) 2006-12-22 2013-01-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Gel useful for the delivery of ophthalmic drugs
CN101342155B (zh) * 2007-07-11 2012-01-04 天津帝士力投资控股集团有限公司 一种(r,r)-福莫特罗吸入粉雾剂及其制备方法
WO2010060875A1 (de) 2008-11-27 2010-06-03 Boehringer Ingelheim International Gmbh Neue pulverförmige kristalline arzneimittel zur inhalation
AU2010210620B2 (en) * 2009-02-03 2016-02-25 Microbion Corporation Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
BR112014009789A2 (pt) * 2011-10-26 2017-04-25 Seattle Children's Res Inst cisteamina no tratamento da doença fibrótica
US9493775B2 (en) * 2012-02-10 2016-11-15 Whitehead Institute For Biomedical Research Inhibition of the glycine cleavage system for treatment of cancer
ITMI20130572A1 (it) 2013-04-10 2014-10-11 Eratech Srl Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione
GB201416716D0 (en) 2014-09-22 2014-11-05 Novabiotics Ltd Use
ITUA20161799A1 (it) * 2016-03-18 2017-09-18 Recordati Ind Chimica E Farmaceutica S P A Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
US10905660B2 (en) * 2016-06-07 2021-02-02 Novabiotics Limited Microparticles

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526735A (ja) 2004-12-30 2008-07-24 ドゥビエル カンパニー リミテッド 噴霧乾燥高分子型コレクチン属タンパク質及びその製造方法
US20120129946A1 (en) 2009-05-23 2012-05-24 Jess Gilbert Thoene Materials and methods for treating viral infections
JP2014515356A (ja) 2011-05-19 2014-06-30 サヴァラ，インク． 乾燥粉末バンコマイシン組成物および関連する方法
JP2013082660A (ja) 2011-10-11 2013-05-09 Nico Puff Corp ニコチン薬の製造法およびその方法により製造される医薬
WO2015054574A1 (en) 2013-10-11 2015-04-16 Zisman Lawrence S Spray dry formulations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Formulation studies on cysteamine for the treatment of nephropathic cystinosis，The Open Access Institutional Repository at Robert Gordon University，2011年，p.1-223
Orphanet J Rare Dis，2014年，Vol.9，Article 189

Also Published As

Publication number Publication date
MX2018014278A (es) 2019-03-14
KR102412212B1 (ko) 2022-06-23
US11369568B2 (en) 2022-06-28
CA3026743C (en) 2024-05-28
RU2018142841A (ru) 2020-06-04
BR112018075221A2 (pt) 2019-03-19
AU2017277897B2 (en) 2022-09-08
CA3026743A1 (en) 2017-12-14
ZA201807852B (en) 2023-05-31
ES2965017T3 (es) 2024-04-10
KR20190016957A (ko) 2019-02-19
EP3463325B1 (en) 2023-11-08
JP2019517541A (ja) 2019-06-24
EP3463325A1 (en) 2019-04-10
SG11201810934TA (en) 2019-01-30
AU2017277897A1 (en) 2018-12-20
US20190175501A1 (en) 2019-06-13
GB201609940D0 (en) 2016-07-20
BR112018075221B1 (pt) 2024-02-06
DK3463325T3 (da) 2024-01-02
FI3463325T3 (fi) 2023-12-19
NZ748596A (en) 2025-06-27
CA3096121C (en) 2022-11-15
WO2017212249A1 (en) 2017-12-14
CA3096121A1 (en) 2017-12-14
CN109310654A (zh) 2019-02-05
RU2018142841A3 (enExample) 2020-09-30

Similar Documents

Publication Publication Date Title
JP7195934B2 (ja) 硫黄含有化合物を含む微小粒子
US10905660B2 (en) Microparticles
JP6392422B2 (ja) 吸入用の一価金属カチオン乾燥粉末
ES2899621T3 (es) Polvos secos catiónicos que comprenden sal de magnesio
CA2981038C (en) Dry powder vancomycin compositions and associated methods
AU2012254999A1 (en) Dry powder vancomycin compositions and associated methods
KR20120003459A (ko) 폐 질환 치료용 건조 분말 제형 및 방법
Manniello et al. Clarithromycin and N-acetylcysteine co-spray-dried powders for pulmonary drug delivery: A focus on drug solubility
JP2008518007A (ja) 肺感染症の処置のための粒子
US10561608B2 (en) Dry powder Vancomycin compositions and associated methods
RU2780397C2 (ru) Микрочастицы, содержащие серосодержащие соединения
Saha et al. Repurposing ebselen as an inhalable dry powder to treat respiratory tract infections
IL263540B2 (en) Microparticles that include a sulfur-containing compound
NZ618002B2 (en) Dry powder vancomycin compositions and associated methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200526

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210330

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210813

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221020

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221214

R150 Certificate of patent or registration of utility model

Ref document number: 7195934

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150